Compare PTON & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTON | AUPH |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2019 | 2014 |
| Metric | PTON | AUPH |
|---|---|---|
| Price | $4.98 | $16.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | $7.90 | ★ $17.86 |
| AVG Volume (30 Days) | ★ 8.2M | 765.8K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 146.67 | ★ 5075.00 |
| EPS | 0.14 | ★ 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $15.83 |
| Revenue Next Year | N/A | $21.30 |
| P/E Ratio | $36.18 | ★ $31.36 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $3.65 | $11.30 |
| 52 Week High | $8.19 | $19.25 |
| Indicator | PTON | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 55.95 |
| Support Level | $4.78 | $15.61 |
| Resistance Level | $5.28 | $17.02 |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 46.94 | 74.67 |
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Products derive revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.